Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB

Brubaker, Linda; Gousse, Angelo E.; Sand, Peter K.; Thompson, Catherine; Patel, Vaishali; Zhou, Jihao; Jenkins, Brenda; Sievert, Karl‐Dietrich

doi:10.1007/s00192-011-1655-1

Cited by 22 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[12][13][14][15] The OAB-PSTQ was administered at baseline, weeks 6 and 12, and at clinic visits every 12 weeks thereafter, and questions were scored on a 6-point scale (1 5 very satisfied, 2 5 somewhat satisfied, 3 5 neutral, 4 5 somewhat dissatisfied, 5 5 very dissatisfied, 6 5 does not apply to me). Lower scores reflected greater satisfaction (a score of 6 for a specific question was scored as missing in the calculations and not included in the total score).…”

Section: 11mentioning

confidence: 99%

“…The Patient Global Assessment (PGA) included 4 single-item, nonvalidated scales that assessed the patient's symptoms, QOL, activity limitations, and overall emotions related to UI secondary to NDO. 14,15 Each item was scored on a scale ranging from 27 to 17 (27 5 a very great deal worse; 26 5 a great deal worse; 25 5 a good deal worse; 24 5 moderately worse; 23 5 somewhat worse; 22 5 a little worse; 21 5 almost the same, hardly any worse at all; 0 5 no change; 11 5 almost the same, hardly any better at all; 12 5 a little better; 13 5 somewhat better; 14 5 moderately better; 15 5 a good deal better; 16 5 a great deal better; 17 5 a very great deal better). At each follow-up visit, the mean group change was calculated by summing the scores (27 to 17) and dividing by the number of complete responses.…”

Section: 11mentioning

confidence: 99%

“…3,14,15,17 Changes in this composite measure reflect the comparative beneficial effect of onabotulinumtoxinA on symptoms as well as patients' lives. Across the domains, patients were more satisfied with the benefits from onabotulinumtoxinA treatment compared with placebo.…”

Section: Patient-reported Outcomes Incontinence Quality Of Lifementioning

confidence: 99%

“…18 Although the PGA is not a validated measure for patients with NDO, it has been used both in patients with OAB 14 and NDO, 15 and the results provide further evidence of the benefit of onabotulinumtoxinA treatment from the patient's perspective.…”

Section: Patient-reported Outcomes Incontinence Quality Of Lifementioning

confidence: 99%

See 3 more Smart Citations

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

Chancellor

Patel²,

Leng³

et al. 2013

Neurology

View full text Add to dashboard Cite

Objective: To evaluate the effects of onabotulinumtoxinA on patient-reported outcomes including health-related quality of life (HRQOL), treatment satisfaction, and treatment goal attainment in patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO).Methods: In this multicenter, double-blind, randomized, placebo-controlled, phase III, 52-week study (ClinicalTrials.gov NCT00311376), patients with UI due to NDO who were not adequately managed with anticholinergic therapy were treated with intradetrusor injections of onabotulinumtoxinA (200 or 300 U) or placebo (0.9% saline). HRQOL measures included the Incontinence Quality of Life (I-QOL) Questionnaire total score, and the 3 domain scores (avoidance and limiting behavior, psychosocial, and social embarrassment), the modified Overactive Bladder Patient Satisfaction with Treatment Questionnaire (OAB-PSTQ), and Patient Global Assessment. Assessments were made at baseline, posttreatment week 6 (primary time point), week 12, and at 12-week intervals.

show abstract

Section: 11mentioning

confidence: 99%

Section: 11mentioning

confidence: 99%

Section: Patient-reported Outcomes Incontinence Quality Of Lifementioning

confidence: 99%

Section: Patient-reported Outcomes Incontinence Quality Of Lifementioning

confidence: 99%

See 2 more Smart Citations

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

Chancellor

Patel²,

Leng³

et al. 2013

Neurology

View full text Add to dashboard Cite

show abstract

“…Only 3 RCTs were included in their review. Since the publication of their review, various new RCTs have been published which included many large sample size studies about botulinum toxin used for idiopathic OAB [6,7,8,9,10,11]. In this paper, we attempt to summarize the data from all RCTs to assess the efficacy and safety of botulinum toxin-A in the management of idiopathic OAB.…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis

Yu¹,

Wang²,

Liu³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Objective: To review the current evidence on the efficacy and safety of botulinum toxin-A in the management of idiopathic overactive bladder (OAB). Methods: A systematic search of PubMed, Embase and the Cochrane Central Search Library was performed. All randomized controlled trials comparing botulinum toxin-A with placebo, different doses and injection techniques, in patients with idiopathic OAB was included. The analyzed outcomes were quantification of symptoms, urodynamic outcomes, quality of life and adverse events. Result: A total of 1,020 participants from 12 randomized controlled trials were included. Botulinum toxin-A was associated with less urinary frequency, less incontinence episodes, improvement in quality of life, higher post-void residual-related catheterization and higher urinary tract infection. Doses of 100-300 U were not consistently differentiated from each other in voiding diary, quality of life and urge urinary incontinence. No statistically significant difference was seen between bladder body and bladder base, bladder body and bladder body plus trigone in urinary retention and urinary tract infection. Conclusion: Botulinum toxin-A is associated with significant improvement in OAB symptoms in patients with idiopathic OAB. However, there is a higher incidence of postoperative urinary retention and urinary infection compared to placebo. Low-dose botulinum toxin-A seems to be the optimum dose that appropriately balances the benefits with adverse events. Trigone inclusion seems as safe and effective as trigone-sparing injection.

show abstract

Patient‐reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity

Chartier‐Kastler¹,

Hepp

Khalaf

et al. 2015

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims:To identify the self-reported treatment goals of patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO), determine whether patients achieved their goals following onabotulinumtoxinA treatment, and assess impact of neurogenic disease (multiple sclerosis or spinal cord injury) and/or clean intermittent catheterization (CIC) on goal achievement. Methods: Data from two Phase III studies of onabotulinumtoxinA 200U (n ¼ 227) or placebo (n ¼ 241) in NDO patients (!14 UI episodes/week; inadequately managed by anticholinergics) were pooled for analysis. At baseline, patients listed their top two qualitative treatment goals, which were distributed into eight subcategories. Six weeks post-treatment, patients rated whether they achieved their goals (5-point Likert scale). The frequency distribution of goals, the proportion of patients who achieved their goals, and goal achievement by etiology and use/non-use of CIC were assessed. Results: At baseline, the most common goals were ''be dry'' (37.9%), ''reduce other urinary symptoms'' (26.4%), and ''improve quality of life/sleep/emotions'' (21.4%). Significantly higher proportions of onabotulinumtoxinAtreated patients achieved their overall goals versus placebo (62.0% vs. 17.2%; P < 0.001). OnabotulinumtoxinA treatment resulted in higher goal achievement in all goal categories, regardless of etiology. CIC use did not negatively impact patients' overall goal achievement; significantly higher proportions of onabotulinumtoxinA-treated patients versus placebo achieved their goals regardless of baseline catheterization use or de novo CIC during the first 6 weeks of the study. Conclusions: The majority of patients with UI due to NDO achieved their self-determined treatment goals following onabotulinumtoxinA 200U therapy, regardless of etiology or CIC use. Neurourol. Urodynam. 35:595-600, 2016.

show abstract

Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB

Abstract: Patients with OAB are more likely to be satisfied and/or achieve their primary treatment goal with onabotulinumtoxinA treatment than with placebo, consistent with symptom improvements.

Cited by 22 publications

References 27 publications

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis

Patient‐reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity

Contact Info

Product

Resources

About